U.S. biopharmaceutical manufacturers have risen to the challenges posed by the COVID-19 pandemic, researching and developing vaccines and therapeutics in record time, ramping up manufacturing to meet global demand, and avoiding sustained supply chain disruptions. This success is due, in part, to significant long-term investments made by PhRMA members in infectious diseases, quality manufacturing and R&D, and resilient global supply chains.